Outcome of Board Meeting
QUICKHEAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Quick Heal Technologies reported a significant deterioration in FY26 performance with consolidated revenue declining 6.6% to ₹261 Cr from ₹279.5 Cr. The company swung to a net loss of ₹10.9 Cr in FY26 versus a profit of ₹5.0 Cr in FY25, primarily due to a sharp contraction in its consumer vertical (down 24.7%) which outweighed enterprise growth (up 22.5%). Q4 FY26 was particularly weak with revenue dropping 25.2% YoY to ₹48.7 Cr and a net loss of ₹19.9 Cr. EBITDA turned deeply negative at ₹(29.4) Cr (FY26) from ₹(6.6) Cr (FY25), with EBITDA margin compressing to -11.3% from -2.4%. The auditors issued an unmodified opinion confirming clean financials. The company also announced appointment of Mr. Rohit Kachroo as Senior Director – IT & Digital Transformation.
The stock is under pressure as Quick Heal reports its first full-year net loss in recent history, driven by consumer segment headwinds and rising hardware costs. While the enterprise segment shows promise and the order book stands at ₹55 Cr+, near-term profitability remains a concern given the ongoing margin compression.